Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE followed by apatinib for advanced hilar cholangiocarcinoma
ChiCTR2000035178Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Sep 2020
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Rivoceranib, paclitaxel and gemcitabine in hilar cholangiocarcinoma (HC), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: objective response rate. Started Sep 2020; status: recruiting.
02
Drugs
Rivoceranibpaclitaxelgemcitabine
03
Conditions
hilar cholangiocarcinoma (HC)
Beyond the preview
Go deeper on ChiCTR2000035178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035178.